Peripheral Blood

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 767868 Experts worldwide ranked by ideXlab platform

Francesco Amenta - One of the best experts on this subject based on the ideXlab platform.

  • Alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of essential hypertensives.
    Journal of Hypertension, 2001
    Co-Authors: Franco Veglio, Seyed Khosrow Tayebati, Alberto Ricci, Elena Bronzetti, P. Mulatero, Domenica Schiavone, Franco Rabbia, Francesco Amenta
    Abstract:

    OBJECTIVE: The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes was investigated in 28 essential hypertensive patients as well as in the Peripheral Blood lymphocytes and aorta of spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. METHODS: Alpha1-adrenergic receptors were quantified by radioligand binding assays, employing [3H]-prazosin as the radioligand in association with compounds displaying different degrees of selectivity for alpha1A-, alpha1B- and alpha1D-adrenergic receptor subtypes. RESULTS: The affinity of [3H]-prazosin binding was similar in Peripheral Blood lymphocytes of different stage essential hypertensive and normotensive subjects or of SHR and age-matched normotensive WKY rats as well as in the aortas of SHR and WKY rats. The radioligand binding assay revealed no change in the expression of alpha1-adrenergic receptors in Peripheral Blood lymphocytes of essential hypertensives compared with normotensive subjects; a moderate decrease of alpha1B-adrenergic receptors and an increase of alpha1D-adrenergic receptors. The relative densities of the alpha1-adrenergic receptor subtypes were similar in the three groups of essential hypertensives. In Peripheral Blood lymphocytes and in aorta of SHR, [3H]-prazosin binding was significantly reduced compared with normotensive WKY rats. The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of SHR was similar to that found in Peripheral Blood lymphocytes of essential hypertensives. CONCLUSIONS: Changes of lymphocyte alpha1-adrenergic receptor subtypes in essential hypertensives are similar to those observed in lymphocytes and vascular tissues of animal models of hypertension. This suggests that assays of lymphocyte alpha1-adrenergic receptors may represent an indirect marker of their involvement in essential hypertension.

  • a1-Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes
    1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    We investigated the expression of a1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription–polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of a1-adrenergic receptors (a1A, a1B, and a1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp a1A-adrenergic receptor fragment, a 689-bp a1B-adrenergic receptor fragment, and a 540-bp a1D-adrenergic receptor fragment. Radioligand binding assay with [ H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0.6560.05 nmol/L and a maximum density of binding sites of 175.3620.5 fmol/10 cells. The pharmacological profile of [H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of a1-adrenergic receptors. Antibodies against a1A-, a1B-, and a1D-receptor subtypes decreased [H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three a1-adrenergic receptor subtypes. Of the three different a1-adrenergic receptor subtypes, the a1B is the most represented and the a1D, the least. Future studies should clarify the functional relevance of a1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of a1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors. (Hypertension. 1999;33:708-712.)

  • Dopamine D1-like receptor subtypes in human Peripheral Blood lymphocytes.
    Journal of Neuroimmunology, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Damiano Zaccheo, Fiorenzo Mignini, Francesco Amenta
    Abstract:

    Abstract Molecular biology studies have shown that human Peripheral Blood lymphocytes express a dopamine D5 receptor, whereas no information is available on dopamine D1 receptor, the other dopamine D1-like receptor subtype. Radioligand binding assay investigations with the nonsubtype selective dopamine D1-like receptor antagonist [ 3 H ]SCH 23390 as radioligand have suggested the presence of a dopamine D5 receptor in human Peripheral Blood lymphocytes. However, so far no evidence was provided as whether or not human Peripheral Blood lymphocytes express a dopamine D1 receptor. In this study, we have investigated dopamine D1 and D5 receptor mRNA and the influence of antibodies against dopamine D1 and D5 receptors on [ 3 H ]SCH 23390 binding to intact human Peripheral Blood lymphocytes. The two receptors were also analyzed by immunocytochemistry. Dopamine D5 receptor, but not D1 mRNA, was detected in human Peripheral Blood lymphocytes. Anti-dopamine D5 receptor antibodies, but not anti-dopamine D1 receptor antibodies, significantly decreased [ 3 H ]SCH 23390 binding to human Peripheral Blood lymphocytes. A dark-brown immunoreactivity was visualized in cytospin centrifuged human Peripheral Blood lymphocytes exposed to anti-dopamine D5, but not to anti-dopamine D1 receptor antibodies. These data collectively indicate that dopamine D5 receptor is the only dopamine D1-like receptor subtype expressed by human Peripheral Blood lymphocytes.

  • alpha1-adrenergic receptor subtypes in human Peripheral Blood lymphocytes.
    Hypertension, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    : We investigated the expression of alpha1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of alpha1-adrenergic receptors (alpha1A, alpha1B, and alpha1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp alpha1A-adrenergic receptor fragment, a 689-bp alpha1B-adrenergic receptor fragment, and a 540-bp alpha1D-adrenergic receptor fragment. Radioligand binding assay with [3H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0. 65+/-0.05 nmol/L and a maximum density of binding sites of 175. 3+/-20.5 fmol/10(6) cells. The pharmacological profile of [3H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of alpha1-adrenergic receptors. Antibodies against alpha1A-, alpha1B-, and alpha1D-receptor subtypes decreased [3H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three alpha1-adrenergic receptor subtypes. Of the three different alpha1-adrenergic receptor subtypes, the alpha1B is the most represented and the alpha1D, the least. Future studies should clarify the functional relevance of alpha1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of alpha1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors.

Alberto Ricci - One of the best experts on this subject based on the ideXlab platform.

  • Alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of essential hypertensives.
    Journal of Hypertension, 2001
    Co-Authors: Franco Veglio, Seyed Khosrow Tayebati, Alberto Ricci, Elena Bronzetti, P. Mulatero, Domenica Schiavone, Franco Rabbia, Francesco Amenta
    Abstract:

    OBJECTIVE: The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes was investigated in 28 essential hypertensive patients as well as in the Peripheral Blood lymphocytes and aorta of spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. METHODS: Alpha1-adrenergic receptors were quantified by radioligand binding assays, employing [3H]-prazosin as the radioligand in association with compounds displaying different degrees of selectivity for alpha1A-, alpha1B- and alpha1D-adrenergic receptor subtypes. RESULTS: The affinity of [3H]-prazosin binding was similar in Peripheral Blood lymphocytes of different stage essential hypertensive and normotensive subjects or of SHR and age-matched normotensive WKY rats as well as in the aortas of SHR and WKY rats. The radioligand binding assay revealed no change in the expression of alpha1-adrenergic receptors in Peripheral Blood lymphocytes of essential hypertensives compared with normotensive subjects; a moderate decrease of alpha1B-adrenergic receptors and an increase of alpha1D-adrenergic receptors. The relative densities of the alpha1-adrenergic receptor subtypes were similar in the three groups of essential hypertensives. In Peripheral Blood lymphocytes and in aorta of SHR, [3H]-prazosin binding was significantly reduced compared with normotensive WKY rats. The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of SHR was similar to that found in Peripheral Blood lymphocytes of essential hypertensives. CONCLUSIONS: Changes of lymphocyte alpha1-adrenergic receptor subtypes in essential hypertensives are similar to those observed in lymphocytes and vascular tissues of animal models of hypertension. This suggests that assays of lymphocyte alpha1-adrenergic receptors may represent an indirect marker of their involvement in essential hypertension.

  • a1-Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes
    1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    We investigated the expression of a1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription–polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of a1-adrenergic receptors (a1A, a1B, and a1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp a1A-adrenergic receptor fragment, a 689-bp a1B-adrenergic receptor fragment, and a 540-bp a1D-adrenergic receptor fragment. Radioligand binding assay with [ H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0.6560.05 nmol/L and a maximum density of binding sites of 175.3620.5 fmol/10 cells. The pharmacological profile of [H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of a1-adrenergic receptors. Antibodies against a1A-, a1B-, and a1D-receptor subtypes decreased [H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three a1-adrenergic receptor subtypes. Of the three different a1-adrenergic receptor subtypes, the a1B is the most represented and the a1D, the least. Future studies should clarify the functional relevance of a1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of a1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors. (Hypertension. 1999;33:708-712.)

  • Dopamine D1-like receptor subtypes in human Peripheral Blood lymphocytes.
    Journal of Neuroimmunology, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Damiano Zaccheo, Fiorenzo Mignini, Francesco Amenta
    Abstract:

    Abstract Molecular biology studies have shown that human Peripheral Blood lymphocytes express a dopamine D5 receptor, whereas no information is available on dopamine D1 receptor, the other dopamine D1-like receptor subtype. Radioligand binding assay investigations with the nonsubtype selective dopamine D1-like receptor antagonist [ 3 H ]SCH 23390 as radioligand have suggested the presence of a dopamine D5 receptor in human Peripheral Blood lymphocytes. However, so far no evidence was provided as whether or not human Peripheral Blood lymphocytes express a dopamine D1 receptor. In this study, we have investigated dopamine D1 and D5 receptor mRNA and the influence of antibodies against dopamine D1 and D5 receptors on [ 3 H ]SCH 23390 binding to intact human Peripheral Blood lymphocytes. The two receptors were also analyzed by immunocytochemistry. Dopamine D5 receptor, but not D1 mRNA, was detected in human Peripheral Blood lymphocytes. Anti-dopamine D5 receptor antibodies, but not anti-dopamine D1 receptor antibodies, significantly decreased [ 3 H ]SCH 23390 binding to human Peripheral Blood lymphocytes. A dark-brown immunoreactivity was visualized in cytospin centrifuged human Peripheral Blood lymphocytes exposed to anti-dopamine D5, but not to anti-dopamine D1 receptor antibodies. These data collectively indicate that dopamine D5 receptor is the only dopamine D1-like receptor subtype expressed by human Peripheral Blood lymphocytes.

  • alpha1-adrenergic receptor subtypes in human Peripheral Blood lymphocytes.
    Hypertension, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    : We investigated the expression of alpha1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of alpha1-adrenergic receptors (alpha1A, alpha1B, and alpha1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp alpha1A-adrenergic receptor fragment, a 689-bp alpha1B-adrenergic receptor fragment, and a 540-bp alpha1D-adrenergic receptor fragment. Radioligand binding assay with [3H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0. 65+/-0.05 nmol/L and a maximum density of binding sites of 175. 3+/-20.5 fmol/10(6) cells. The pharmacological profile of [3H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of alpha1-adrenergic receptors. Antibodies against alpha1A-, alpha1B-, and alpha1D-receptor subtypes decreased [3H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three alpha1-adrenergic receptor subtypes. Of the three different alpha1-adrenergic receptor subtypes, the alpha1B is the most represented and the alpha1D, the least. Future studies should clarify the functional relevance of alpha1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of alpha1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors.

Stephen Couban - One of the best experts on this subject based on the ideXlab platform.

  • Peripheral Blood stem cells versus bone marrow from unrelated donors
    The New England Journal of Medicine, 2012
    Co-Authors: Claudio Anasetti, Brent R Logan, Stephanie J Lee, Edmund K Waller, Daniel J Weisdorf, John R Wingard, Corey Cutler, Peter Westervelt, Ann E Woolfrey, Stephen Couban
    Abstract:

    BACKGROUND Randomized trials have shown that the transplantation of filgrastim-mobilized Peripheral-Blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that Peripheral-Blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia. METHODS We conducted a phase 3, multicenter, randomized trial of transplantation of Peripheral-Blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1:1 ratio to Peripheral-Blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37). RESULTS The overall survival rate at 2 years in the Peripheral-Blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P = 0.29), with an absolute difference of 5 percentage points (95% CI, −3 to 14). The overall incidence of graft failure in the Peripheral-Blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P = 0.002). The incidence of chronic GVHD at 2 years in the Peripheral-Blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P = 0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse. CONCLUSIONS We did not detect significant survival differences between Peripheral-Blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that Peripheral-Blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute–National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.)

Seyed Khosrow Tayebati - One of the best experts on this subject based on the ideXlab platform.

  • Alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of essential hypertensives.
    Journal of Hypertension, 2001
    Co-Authors: Franco Veglio, Seyed Khosrow Tayebati, Alberto Ricci, Elena Bronzetti, P. Mulatero, Domenica Schiavone, Franco Rabbia, Francesco Amenta
    Abstract:

    OBJECTIVE: The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes was investigated in 28 essential hypertensive patients as well as in the Peripheral Blood lymphocytes and aorta of spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. METHODS: Alpha1-adrenergic receptors were quantified by radioligand binding assays, employing [3H]-prazosin as the radioligand in association with compounds displaying different degrees of selectivity for alpha1A-, alpha1B- and alpha1D-adrenergic receptor subtypes. RESULTS: The affinity of [3H]-prazosin binding was similar in Peripheral Blood lymphocytes of different stage essential hypertensive and normotensive subjects or of SHR and age-matched normotensive WKY rats as well as in the aortas of SHR and WKY rats. The radioligand binding assay revealed no change in the expression of alpha1-adrenergic receptors in Peripheral Blood lymphocytes of essential hypertensives compared with normotensive subjects; a moderate decrease of alpha1B-adrenergic receptors and an increase of alpha1D-adrenergic receptors. The relative densities of the alpha1-adrenergic receptor subtypes were similar in the three groups of essential hypertensives. In Peripheral Blood lymphocytes and in aorta of SHR, [3H]-prazosin binding was significantly reduced compared with normotensive WKY rats. The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of SHR was similar to that found in Peripheral Blood lymphocytes of essential hypertensives. CONCLUSIONS: Changes of lymphocyte alpha1-adrenergic receptor subtypes in essential hypertensives are similar to those observed in lymphocytes and vascular tissues of animal models of hypertension. This suggests that assays of lymphocyte alpha1-adrenergic receptors may represent an indirect marker of their involvement in essential hypertension.

  • a1-Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes
    1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    We investigated the expression of a1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription–polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of a1-adrenergic receptors (a1A, a1B, and a1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp a1A-adrenergic receptor fragment, a 689-bp a1B-adrenergic receptor fragment, and a 540-bp a1D-adrenergic receptor fragment. Radioligand binding assay with [ H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0.6560.05 nmol/L and a maximum density of binding sites of 175.3620.5 fmol/10 cells. The pharmacological profile of [H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of a1-adrenergic receptors. Antibodies against a1A-, a1B-, and a1D-receptor subtypes decreased [H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three a1-adrenergic receptor subtypes. Of the three different a1-adrenergic receptor subtypes, the a1B is the most represented and the a1D, the least. Future studies should clarify the functional relevance of a1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of a1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors. (Hypertension. 1999;33:708-712.)

  • Dopamine D1-like receptor subtypes in human Peripheral Blood lymphocytes.
    Journal of Neuroimmunology, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Damiano Zaccheo, Fiorenzo Mignini, Francesco Amenta
    Abstract:

    Abstract Molecular biology studies have shown that human Peripheral Blood lymphocytes express a dopamine D5 receptor, whereas no information is available on dopamine D1 receptor, the other dopamine D1-like receptor subtype. Radioligand binding assay investigations with the nonsubtype selective dopamine D1-like receptor antagonist [ 3 H ]SCH 23390 as radioligand have suggested the presence of a dopamine D5 receptor in human Peripheral Blood lymphocytes. However, so far no evidence was provided as whether or not human Peripheral Blood lymphocytes express a dopamine D1 receptor. In this study, we have investigated dopamine D1 and D5 receptor mRNA and the influence of antibodies against dopamine D1 and D5 receptors on [ 3 H ]SCH 23390 binding to intact human Peripheral Blood lymphocytes. The two receptors were also analyzed by immunocytochemistry. Dopamine D5 receptor, but not D1 mRNA, was detected in human Peripheral Blood lymphocytes. Anti-dopamine D5 receptor antibodies, but not anti-dopamine D1 receptor antibodies, significantly decreased [ 3 H ]SCH 23390 binding to human Peripheral Blood lymphocytes. A dark-brown immunoreactivity was visualized in cytospin centrifuged human Peripheral Blood lymphocytes exposed to anti-dopamine D5, but not to anti-dopamine D1 receptor antibodies. These data collectively indicate that dopamine D5 receptor is the only dopamine D1-like receptor subtype expressed by human Peripheral Blood lymphocytes.

  • alpha1-adrenergic receptor subtypes in human Peripheral Blood lymphocytes.
    Hypertension, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    : We investigated the expression of alpha1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of alpha1-adrenergic receptors (alpha1A, alpha1B, and alpha1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp alpha1A-adrenergic receptor fragment, a 689-bp alpha1B-adrenergic receptor fragment, and a 540-bp alpha1D-adrenergic receptor fragment. Radioligand binding assay with [3H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0. 65+/-0.05 nmol/L and a maximum density of binding sites of 175. 3+/-20.5 fmol/10(6) cells. The pharmacological profile of [3H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of alpha1-adrenergic receptors. Antibodies against alpha1A-, alpha1B-, and alpha1D-receptor subtypes decreased [3H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three alpha1-adrenergic receptor subtypes. Of the three different alpha1-adrenergic receptor subtypes, the alpha1B is the most represented and the alpha1D, the least. Future studies should clarify the functional relevance of alpha1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of alpha1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors.

Elena Bronzetti - One of the best experts on this subject based on the ideXlab platform.

  • Alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of essential hypertensives.
    Journal of Hypertension, 2001
    Co-Authors: Franco Veglio, Seyed Khosrow Tayebati, Alberto Ricci, Elena Bronzetti, P. Mulatero, Domenica Schiavone, Franco Rabbia, Francesco Amenta
    Abstract:

    OBJECTIVE: The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes was investigated in 28 essential hypertensive patients as well as in the Peripheral Blood lymphocytes and aorta of spontaneously hypertensive rats (SHR) and normotensive Wistar-Kyoto (WKY) rats. METHODS: Alpha1-adrenergic receptors were quantified by radioligand binding assays, employing [3H]-prazosin as the radioligand in association with compounds displaying different degrees of selectivity for alpha1A-, alpha1B- and alpha1D-adrenergic receptor subtypes. RESULTS: The affinity of [3H]-prazosin binding was similar in Peripheral Blood lymphocytes of different stage essential hypertensive and normotensive subjects or of SHR and age-matched normotensive WKY rats as well as in the aortas of SHR and WKY rats. The radioligand binding assay revealed no change in the expression of alpha1-adrenergic receptors in Peripheral Blood lymphocytes of essential hypertensives compared with normotensive subjects; a moderate decrease of alpha1B-adrenergic receptors and an increase of alpha1D-adrenergic receptors. The relative densities of the alpha1-adrenergic receptor subtypes were similar in the three groups of essential hypertensives. In Peripheral Blood lymphocytes and in aorta of SHR, [3H]-prazosin binding was significantly reduced compared with normotensive WKY rats. The expression of alpha1-adrenergic receptor subtypes in Peripheral Blood lymphocytes of SHR was similar to that found in Peripheral Blood lymphocytes of essential hypertensives. CONCLUSIONS: Changes of lymphocyte alpha1-adrenergic receptor subtypes in essential hypertensives are similar to those observed in lymphocytes and vascular tissues of animal models of hypertension. This suggests that assays of lymphocyte alpha1-adrenergic receptors may represent an indirect marker of their involvement in essential hypertension.

  • a1-Adrenergic Receptor Subtypes in Human Peripheral Blood Lymphocytes
    1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    We investigated the expression of a1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription–polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of a1-adrenergic receptors (a1A, a1B, and a1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp a1A-adrenergic receptor fragment, a 689-bp a1B-adrenergic receptor fragment, and a 540-bp a1D-adrenergic receptor fragment. Radioligand binding assay with [ H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0.6560.05 nmol/L and a maximum density of binding sites of 175.3620.5 fmol/10 cells. The pharmacological profile of [H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of a1-adrenergic receptors. Antibodies against a1A-, a1B-, and a1D-receptor subtypes decreased [H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three a1-adrenergic receptor subtypes. Of the three different a1-adrenergic receptor subtypes, the a1B is the most represented and the a1D, the least. Future studies should clarify the functional relevance of a1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of a1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors. (Hypertension. 1999;33:708-712.)

  • Dopamine D1-like receptor subtypes in human Peripheral Blood lymphocytes.
    Journal of Neuroimmunology, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Damiano Zaccheo, Fiorenzo Mignini, Francesco Amenta
    Abstract:

    Abstract Molecular biology studies have shown that human Peripheral Blood lymphocytes express a dopamine D5 receptor, whereas no information is available on dopamine D1 receptor, the other dopamine D1-like receptor subtype. Radioligand binding assay investigations with the nonsubtype selective dopamine D1-like receptor antagonist [ 3 H ]SCH 23390 as radioligand have suggested the presence of a dopamine D5 receptor in human Peripheral Blood lymphocytes. However, so far no evidence was provided as whether or not human Peripheral Blood lymphocytes express a dopamine D1 receptor. In this study, we have investigated dopamine D1 and D5 receptor mRNA and the influence of antibodies against dopamine D1 and D5 receptors on [ 3 H ]SCH 23390 binding to intact human Peripheral Blood lymphocytes. The two receptors were also analyzed by immunocytochemistry. Dopamine D5 receptor, but not D1 mRNA, was detected in human Peripheral Blood lymphocytes. Anti-dopamine D5 receptor antibodies, but not anti-dopamine D1 receptor antibodies, significantly decreased [ 3 H ]SCH 23390 binding to human Peripheral Blood lymphocytes. A dark-brown immunoreactivity was visualized in cytospin centrifuged human Peripheral Blood lymphocytes exposed to anti-dopamine D5, but not to anti-dopamine D1 receptor antibodies. These data collectively indicate that dopamine D5 receptor is the only dopamine D1-like receptor subtype expressed by human Peripheral Blood lymphocytes.

  • alpha1-adrenergic receptor subtypes in human Peripheral Blood lymphocytes.
    Hypertension, 1999
    Co-Authors: Alberto Ricci, Seyed Khosrow Tayebati, Elena Bronzetti, Andrea Conterno, Stefania Greco, P. Mulatero, Marina Schena, Domenica Schiavone, Franco Veglio, Francesco Amenta
    Abstract:

    : We investigated the expression of alpha1-adrenergic receptor subtypes in intact human Peripheral Blood lymphocytes using reverse transcription-polymerase chain reaction (RT-PCR) and radioligand binding assay techniques combined with antibodies against the three subtypes of alpha1-adrenergic receptors (alpha1A, alpha1B, and alpha1D). RT-PCR amplified in Peripheral Blood lymphocytes a 348-bp alpha1A-adrenergic receptor fragment, a 689-bp alpha1B-adrenergic receptor fragment, and a 540-bp alpha1D-adrenergic receptor fragment. Radioligand binding assay with [3H]prazosin as radioligand revealed a high-affinity binding with a dissociation constant value of 0. 65+/-0.05 nmol/L and a maximum density of binding sites of 175. 3+/-20.5 fmol/10(6) cells. The pharmacological profile of [3H]prazosin binding to human Peripheral Blood lymphocytes was consistent with the labeling of alpha1-adrenergic receptors. Antibodies against alpha1A-, alpha1B-, and alpha1D-receptor subtypes decreased [3H]prazosin binding to a different extent. This indicates that human Peripheral Blood lymphocytes express the three alpha1-adrenergic receptor subtypes. Of the three different alpha1-adrenergic receptor subtypes, the alpha1B is the most represented and the alpha1D, the least. Future studies should clarify the functional relevance of alpha1-adrenergic receptors expressed by Peripheral Blood lymphocytes. The identification of these sites may represent a step for evaluating whether they represent a marker of alpha1-adrenergic receptors in cardiovascular disorders or for assessing responses to drug treatment on these receptors.